CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors

Wednesday, October 31, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

COSTA MESA, Calif., Oct. 31 CNS Response, Inc.(OTC Bulletin Board: CNSO) announced today that Henry T. Harbin, MD has beenappointed to the Company's Board of Directors. A psychiatrist with over 30-years experience in the behavioral health field, Dr. Harbin has served as theCEO of two national behavioral health care companies and has held numeroussenior positions in both the public and private mental health sectors.

Len Brandt, chairman and CEO of CNS Response, commented, "CNS Response isextremely fortunate to add Dr. Harbin's experience and acumen to our Board ofDirectors. I simply don't know anyone who has been more at the forefront ofadvancing behavioral healthcare management these past twenty-five years.Beyond that, Dr. Harbin is a creative force who has already influenced ourthinking on initiatives to accelerate the impact that the objective guidanceof rEEG(SM) can make for patients and payers alike."

Among his past accomplishments, Dr. Harbin served as Commissioner of thePresident's New Freedom Commission on Mental Health from 2002 to 2003,chairing the subcommittee for the Interface between Mental Health and GeneralMedicine. In addition to his Federal government experience, Dr. Harbin alsospent 10 years in the public mental health system in Maryland, serving asDirector of the State Mental Health Authority for three of those years.

As the chairman, CEO and President of Magellan Health Services, thecountry's leading behavioral managed care organization, Dr. Harbin led acompany with approximately 6,500 employees and revenues of $1.7 billion.During his tenure from 1998 to 2004, Magellan managed the mental health andsubstance abuse benefits of approximately 70 million Americans includingpersons who were insured by private employers, Medicaid and Medicare. Priorto Magellan, Dr. Harbin worked for Green Spring Health Services, Inc., one ofthe largest managed behavioral health organizations in the country. Dr.Harbin held several executive positions at the company, including five yearsas its president and CEO.

Among his achievements in research, Dr. Harbin was a principalinvestigator and project director for multiple studies at the University ofMaryland's Institute of Psychiatry and Human Behavior, and has served as areviewer for the American Journal of Psychiatry, Journal of Nervous and MentalDisease, and Hospital & Community Psychiatry. Dr. Harbin has also beenpublished in over 10 peer-reviewed articles.

Dave Jones, Managing Partner of Sail Venture Capital and a member of theCNS Response Board of Directors, remarked, "The experience and enthusiasm ofthe people becoming associated with CNS Response, including Dr. Henry Harbin,our new President, George Carpenter, the new Chief Medical Officer, DanielHoffman, MD, and others joining Len, combined with the core team, allows thiscompany to capitalize on its extraordinary vision and opportunity."

About CNS Response

CNS Response is a life-sciences data company focused on thecommercialization of the first patented commercial system that guidespsychiatrists and other physicians to determine proper treatments for patientswith behavioral (mental or addictive) disorders. This technology allows CNSResponse to create and provide simple reports ("rEEG(SM) Reports") thatspecifically guide physicians to treatment strategies based on the patient'sown physiology.

rEEG(SM) utilizes traditional electroencephalography (EEG) in conjunctionwith a normative database and a proprietary clinical (symptomatic) database toidentify the following: (1) medication classes most likely to be needed; and(2) medications within these classes with the most probable treatmentpotential for each patient. Reports are provided to physicians in arelationship analogous to that of a reference laboratory. Prospective,retrospective and field studies of treatment-resistant patients have reportedt

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store